已发表论文

CDK3、CDK5 和 CDK8 蛋白作为结直肠癌患者的预后和潜在生物标志物

 

Authors Wang D, Zhou Y, Hua L, Li J, Zhu N, Liu Y

Received 24 November 2021

Accepted for publication 16 February 2022

Published 27 February 2022 Volume 2022:15 Pages 2233—2245

DOI https://doi.org/10.2147/IJGM.S349576

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 3

Editor who approved publication: Dr Scott Fraser

Introduction: In the cell cycle, cyclin-dependent kinases (CDKs) play a positive regulatory role, which is essential for normal cell growth, but the expression pattern and prognostic significance of the CDK family in colorectal cancer (CRC) have not been systematically investigated.
Methods: In our study, we analyzed and visualized the expression of CDKs in CRC using TCGA, GEPIA, GSCALite, TIMER, HPA database, and R language CDKs risk model was constructed.
Results: Overall, CDKs (CDK1, CDK2, CDK3, CDK4, CDK5, CDK6, CDK7 and CDK8) were differentially expressed between normal controls and colorectal cancer. Three CDKs genes (CDK3, CDK5 and CDK8) associated with prognosis were obtained by univariate and multivariate Cox and LASSO regression analysis. In CRC, CDK3, CDK5 and CDK8 are significantly associated with expression levels of recognized immune infiltrates.
Conclusion: CDK3, CDK5 and CDK8 are potential diagnostic markers for CRC; meanwhile, CDK3, CDK5 and CDK8 are potential prognostic markers for CRC; studying the relationship between CDKs and tumor immunology may be helpful for immunotherapy of CRC, and more studies are needed to confirm these results.
Keywords: colorectal cancer, cyclin-dependent kinases family, mRNA expression, prognosis, risk score model